Down Regulated Protein C Plasma Levels in the Absence of Factor V Leiden Mutation in HIV Patients: An Observational Study in Maiduguri, North-Eastern Nigeria
Simon O. Obi1, Ballah Akawu Denue2*, Ifeanyi Chukwu O. Martin3, Marycelin M. Baba1, Grace I. Amilo4, Salihu Aliyu Kwayabura5, Obi Ejeatulu6
1Department of Medical Lab, Science College of Medicine, University of Maiduguri, Maiduguri, Nigeria.
2Department of Medicine, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria.
3Department of Immunology, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria.
4Department of Haematology, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria.
5Department of Obstetrics and Gynaecology, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria.
6Department of Pharmacology, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria.
DOI: 10.4236/wja.2015.52009   PDF    HTML   XML   2,804 Downloads   3,428 Views   Citations


Background: As life expectancy of HIV-infected patients increases with use of highly active antiretroviral therapy (HAART), protean haematologic manifestation including decreased activity of natural anticoagulants such as protein C may occur in the absence of genetic risk factors. Based on this preposition, we assessed the plasma level of protein C, and prevalence of factor V Leiden mutation among HIV-infected individuals. Our cohort consisted of 499 HIV-infected patients, of which 250 had AIDS, while 249 were either asymptomatic or had minor mucocutaneous infection consistent with WHO clinical stages I and II without features of AIDS. We also evaluated 251 healthy, HIV-negative subjects as controls. All participants were tested for plasma protein C levels and factor V Leiden (FVL) mutation (Arg 506 Gln) by automation and amplification created restriction enzyme site (ACRES) polymerase chain reaction, respectively. The prevalence of reduced protein C plasma levels among HIV positive patients was 20%; it was more prevalent among those that had AIDS compared with those without features of AIDS, but within WHO clinical stage I and II, (93.3% vs 6.7%) respectively. None of the control patients had either reduced protein C nor FVL mutation. All participants that demonstrated reduced protein C plasma levels demonstrated normal FVL genotype (1691G/G). Conclusion: Decreased protein C plasma levels can occur in HIV-infected patients in the absence of factor V Leiden mutation. The risk increases with severity of the disease. Deranged protein C plasma level increases the risk of hypercoagulable state in patients with advanced HIV disease; it should be considered among the causes of thrombo embolism in this group of patients.

Share and Cite:

Obi, S. , Denue, B. , O. Martin, I. , M. Baba, M. , Amilo, G. , Kwayabura, S. and Ejeatulu, O. (2015) Down Regulated Protein C Plasma Levels in the Absence of Factor V Leiden Mutation in HIV Patients: An Observational Study in Maiduguri, North-Eastern Nigeria. World Journal of AIDS, 5, 76-82. doi: 10.4236/wja.2015.52009.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Shen, Y.P. and Frankel, E.P. (2004) Thrombosis and Hypercoagulable State in HIV Infected Patients. Clinical and Applied Thrombosis/Hemostasis, 10, 270-280.
[2] Klein, S.K., Slim, E.J., de Kruifde, M.D., Keller, T.T., Ten Cate, H. and Van Gorp, E. (2005) Is Chronic HIV Infection Associated with Venous Thrombotic Disease? A Systematic Review. Netherland Journal of Medicine, 69, 129-136.
[3] Eyal, A. and Vella, M. (2009) HIV and Venous Thrombotic Events. South African Journal of Surgery, 7, 93-95.
[4] Opie, J. (2012) Haematological Complications of HIV Infection. The South African Medical Journal, 102, 465-468.
[5] Walker, I.D. (2005) Inherited Thrombophila. In: Hoffbrand, V., Catovsky, D. and Taddenham, E.G.D., Eds., Postgraduate Hematology, 5th Edition, Wiley India, Blackwell Publishing Ltd., Oxford, 885-889.
[6] Geoffery, K.C., Edward, G.D. and John, H.M. (2005) Protein C Pathway—Inhibition of Co Factors FVa and FVllla. Post Graduate Haematology, 5th Edition, Blackwell Publishing Ltd., Oxford, 802-804.
[7] Dahlback, B. and Vittoutreix, B.O. (2003) Molecular Recognition in the Protein C Anticoagulant Pathway. Journal of Thrombosis and Haemostasis, 1, 1525-1531.
[8] Bauer, K.A. (2003) Management of Thrombophilia. Journal of Thrombosis and Haemostasis, 1, 1429-1434.
[9] Stimmiler, M.M., Quismorio, F.P., McGehee, W.E., Boylan, T. and Sharma, O.P. (1989) Anticardiolipin Antibodies in Acquire Immunode Ficiency Syndrome. Archival international Medicine, 149, 1833-1834.
[10] Ankri, A., Bonmarchand, M., Coutellier, A., Hensons, A. and Karmochkine, M. (1999) Antiphospholipid Antibodies Are Epiphenomenon in HIV Infected Patients. AIDS, 13, 1282-1283.
[11] Bibas, M., Gianluigi, B. and Andrea, A. (2011) HIV Associated Venous Thomboembolism. Mediterrenian Journal of Hematology and Infectious Disease, 3, 2035-3006.
[12] Hooper, G., Philip, J. and Robeiro, A. (1994) Tumor Necrosis Factor-Alpha down Regulates Protein S Secretion in Human Micro Vascular and Umblical Vein Endothehal Cells. Hep G2 Hepatoma Cell Line. Blood, 84, 483-489.
[13] Esmon, C.T. (2000) The Endothelial Cell Protein C Receptor. Thrombosis and Haemostasis, 83, 639-643.
[14] Beverly, J. (2005) Hunt and Michael Greave. Acquired Venous Thrombosis. Postgraduate Haem-atology, 5th Edition, Black Well Publishing, Oxford, 905.
[15] Javier, C. (2007) Immune Activation and Increased Prevalence of Thrombosis in HIV Infection. Journal of AIDS, 46, 375-376.
[16] World Health Organisation (2007) WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. World Health Organisation.
[17] (1993) Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults.
[18] Kraus, M., Protein, C. and Protein, S. (1998) Factor V Leiden. In: Thomas, L., Ed., Clinical Laboratory Diagnostics Franktar. TH Book Verlag, Frankfurt, 621-625.
[19] CLSI (2008) Collection, Transport, and Processing of Blood Specimen for Testing Plasma Based Coagulation Assay and Molecular Hemostasis Assay. Approved Guide Line 5th Edition CLSI Document H21-A5.
[20] Siemens Healthcare Diagnostic Products (2008) Berichrom Protein C Reagent Kit, Procedure Manual OUVVG15 E0502 (194) CS/ST.
[21] Erbe, M., Richerts, V., Bauesacha, M. and Lindhood, E. (2003) Acquired Protein C and Protein S Deficiencies in HIV Infected Patients. Clinical and Applied Thrombosis and Haemostasis, 9, 325-331.
[22] Katie, K. and Melissa, B. (2011) Risk Factors for Venous Thromboembolism in Patients with HIV-Infection. Pharmacotherapy, 30, 1293-1304.
[23] Christine, C. (2005) Haematology in HIV Disease. Postgraduate Haematology, 5th Edition, Blackwell Publishing Ltd., Oxford, 381-394.
[24] Mayne, P.D. (2005) Liver and Gallstones in Clinical Chemistry in Diagnosis and Treatment. 6th Edition, India Book Power (Formerly ELST), 283-284.
[25] De Visser, M.C., Rosendaal, F.R. and Bertina, R.M. (1999) A Reduced Sensitivity for Activated Protein C in the Absence of Factor V Leiden Increases the Risk of Venous Thrombosis. Blood, 93, 1271-1276.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.